Capsaicin Is Not Recommended for Chronic Low‑Back Pain – Evidence‑Based Guideline Summary

1. Rationale for Excluding Capsaicin in Low‑Back Pain

• The 2022 CDC guideline (MMWR Recommendations and Reports) states that high‑concentration capsaicin patches are recommended only for neuropathic pain conditions such as diabetic neuropathy and post‑herpetic neuralgia, and are not indicated for chronic mechanical low‑back pain. 1
• The same CDC guideline notes that evidence for topical lidocaine and capsaicin is limited, even when used for neuropathic pain, indicating a weak evidence base for these agents in any chronic pain indication. 2
• The 2017 American College of Physicians systematic review (Annals of Internal Medicine) found insufficient evidence to support the inclusion of topical capsaicin (or lidocaine) in treatment recommendations for chronic low‑back pain. 3

2. Evidence‑Based Pharmacologic Alternatives

2.1 First‑Line Analgesic

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) remain the first‑line pharmacologic option; they reduce chronic low‑back pain by approximately 12 points on a 0–100 pain scale when used at the lowest effective dose for the shortest duration. 2

2.2 Second‑Line – Duloxetine

• Duloxetine (starting at 30 mg daily for one week, then titrating to 60 mg daily if tolerated) is recommended as the next pharmacologic step when NSAIDs and physical therapy are insufficient. 1
• The CDC guideline assigns moderate‑quality evidence to duloxetine for achieving small but clinically meaningful improvements in chronic low‑back pain. 1
• Duloxetine is FDA‑approved for chronic musculoskeletal pain and shows particular effectiveness in older adult populations. 6

2.3 Third‑Line – Tramadol (Cautious Use)

• If duloxetine is ineffective or not tolerated, tramadol may be considered as a third‑line option, with careful monitoring for adverse effects. 6

3. Non‑Pharmacologic Recommendations

• The American College of Physicians strongly recommends continuing or adding exercise therapy, spinal manipulation, massage, or cognitive‑behavioral therapy alongside pharmacologic treatment for chronic low‑back pain. 6

4. Mechanistic and Safety Considerations

• Capsaicin’s mechanism—desensitization of cutaneous nociceptors—is suited to neuropathic pain with cutaneous hypersensitivity, not to the deep somatic pain of mechanical low‑back pain. 1
• Using capsaicin for low‑back pain would expose patients to significant local skin reactions (≈ 33 % of users) without demonstrable benefit, potentially delaying effective therapy such as duloxetine. 1